Top

Published in:

01-02-2015 | CUTTING EDGE IN AUTOIMMUNITY

The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value

Authors: Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Orsolya Csuka, Timea Balatoni, Laszlo Toth, Klara Eles, Szabolcs Horvath, Gyorgy Naszados, Judit Olasz, Balazs Banky, Jozsef Toth, Maria Godeny, Francesco M. Marincola, Miklos Kasler, Yehuda Shoenfeld

Published in: Immunologic Research | Issue 1-2/2015

Abstract

We aim to harness the natural humoral immune response by various technologies to get novel biomarkers. A complex antibody analysis in sera and in the tumor microenvironment leads to reveal tumor-specific antibodies. More strategies were introduced to select the most effective one to identify potential tumor antigen-binding capacity of the host. Epstein–Barr virus transformation and cloning with limiting dilution assay, magnetic cell sorting and antibody phage display with further methodological improvements were used in epithelial and neuroectodermal cancers. Column-purified sera of patient with melanoma were tested by immunofluorescence assay, while sera of further melanoma patients were processed for membrane-binding enzyme-linked immunosorbent assay. Some supernatants of selected B cell clones and purified antibodies showed considerable cancer cell binding capacity by immunofluorescence FACS analysis and confocal laser microscopy. Our native tumor cell membrane preparations helped to test soluble scFv and patients’ sera for tumor binder antibodies. A complex tumor immunological study was introduced for patients with melanoma (ethical permission: ETT TUKEB 16462-02/2010); peripheral blood (n = 57) and surgically removed primary or metastatic tumors (n = 44) were gathered and processed at cellular immunological level. The technological developments proved to be important steps forward to the next antibody profile analyses at DNA sequence level. Cancer cell binding of patient-derived antibodies and natural immunoglobulin preparations of pooled plasma product intravenous immunoglobulins support the importance of natural human antibodies. Important cancer diagnostics and novel anticancer strategies are going to be built on these tools.

Ascierto PA, Marincola FM. What have we learned from cancer immunotherapy in the last 3 years? J Transl Med. 2014;12(1):141. doi:10.1186/1479-5876-12-141.PubMedCentralPubMedCrossRef

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9(1):214. doi:10.1186/1479-5876-9-214.

Shurin MR, Umansky V, Malyguine A, Hurwitz AA, Apte RN, Whiteside T, et al. Cellular and molecular pathways in the tumor immunoenvironment: 3rd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, 22–25 April 2013, Krakow, Poland. Cancer Immunol Immunother. 2014;63(1):73–80.

Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA. 2011;108(1):266–71. doi:10.1073/pnas.1016791108.

Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8. doi:10.4049/jimmunol.1490019.PubMedCrossRef

Witz IP. Yin-Yang activities and vicious cycles in the tumor microenvironment. Cancer Res. 2010;68:9–13.

Ferrone S, Whiteside TL. Histocompatibility antigens, tumor microenvironment and escape mechanisms utilized by tumor cells, chap. 2. In: Yefenof E, editor. Innate and adaptive immunity in the tumor microenvironment. New York: Springer; 2008. p. 35–51.

Maman S, Witz IP. The metastatic microenvironment, chap. 2. In: Shurin MR, Umansky V, Shurin MR, Malyguine A, editors. The tumor immunoenvironment. Dordrecht: Springer; 2013. p. 15–38.

Malyguine A, Umansky V, Shurin MR. Role of the immunological environment in cancer initiation, development and progression, chap. 1. In: Shurin MR, Umansky V, Shurin MR, Malyguine A, editors. The tumor immunoenvironment. New York: Springer; 2011. p. 1–12.

10.

Shurin MR, Lu L, Kalinski P, Stewart-Akels AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunpathol. 1999;21:339–59.

11.

Hakomori S, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. JNCI. 1983;71:231–51.

12.

Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA. 2002;99:10231–3.

13.

Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest. 2007;87(9):851–7.

14.

Ravindranath MH, Ravindranath DMH. Human antiganglioside autoantibodies, chap. 37. In: Shoenfeld Y, Gerschwin ME, Meroni PL, editors. Autoantibodies, 2nd ed. Amsterdam: Elsevier; 2007. p. 277–83.

15.

Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–44.

16.

Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma. Lancet. 1989;1(8641):786–7.

17.

Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol. 2005;175:2278–85.

18.

Daniotti JL, Vilcaes AA, Demichelis VT, Ruggiero FM, Rodriguez-Walker M. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol. 2013;3:306–18. doi:10.3389/fonc.2013.00306.

19.

Ravindranath MH, Yesowitch P, Sumobay C, Morton D. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol. 2007;3:201–14.

20.

Kotlan B, Gruel N, Zafrani B, Füredi G, Foldi J, Petranyi GG, et al. Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. Immunol Lett. 1999;65:143–51.

21.

Conra K, Bachmann M. Autoantibodies. In: Shoenfeld Y, Gerschwin ME, Meroni PL, editors. Autoantibodies, summary 2/e. 2nd ed. Amsterdam: Elsevier; 2007. p. 423–35.

22.

Vollmers HP, Brandlein S. Nature’s best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum Antibodies. 2002;11:131–42.

23.

Kotlan B, Toth J, McKnight M, Glassy MC. Characteristics of tumor gangliosides revealed by B cells infiltrating human breast carcinomas. Hum Antibodies. 2006;15(1, 2):9–13.

24.

Sherer Y, Levy Y, Shoenfeld Y. IVIG in autoimmunity and cancer efficacy versus safety. Expert Opin Drug Saf. 2002;1:153–8.

25.

Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol. 2009;158:43–50.

26.

Kotlan B, Stroncek DF, Marincola FM. Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. Immunotherapy. 2009;1(6):995–1015. doi:10.2217/imt.09.67.

27.

Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol. 1996;105(1):84–8.

28.

Stein R, Witz IP, Ovadia J, Goldenberg DM, Yron I. CD5+ B cells and naturally occurring autoantibodies in cancer patients. Clin Exp Immunol. 1991;85(3):418–23.

29.

Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spreaf in mice. Int. Immunol. 1999;11:1247–52.

30.

Merimsky O, Meller I, Moshe I, Bar-Yehuda S, Shoenfeld Y, Fishman P. A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int J Oncol. 2002;20(4):839–43.

31.

Fishman P, Shoenfeld Y. Intravenous immunoglobulin (IVIG) as an inhibitor of tumor growth: from autoimmunity to cancer, chap VII. In: Heidt PJ, Rusch VD, van der Waaij D, editors. Old Herborn University seminar monograph. Germany: Herborn Litrature, Herborn Dill; 2000. p. 93–107.

32.

Shoenfeld Y, Levy Y, Fishman P. Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. IMAJ. 2001;3:698–9.

33.

Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis and malignant conditions: our experience with 200 patients. J Clin Immunol. 2004;24:107–14.

34.

Kotlan B, Glassy MC. Antibody phage display. Overview of a powerful technology that has quickly translated to the clinic. In: Aitken R, editor. Methods in molecular biology, vol. 562. Humana Press Inc.; 2009. p. 1–16.

35.

Ladanyi A, Timar J, Bocsi J, Tovari J, Lapis K. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res. 1995;5:83–6.

36.

Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.

37.

Shoenfeld Y, Blank M, Branch DR, Vassilev T, Käsermann F, Bayry J, et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol. 2014;14(5):349. doi:10.1038/nri3401-c1.

Title: The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value
Authors: Beatrix Kotlan
Gabriella Liszkay
Miri Blank
Orsolya Csuka
Timea Balatoni
Laszlo Toth
Klara Eles
Szabolcs Horvath
Gyorgy Naszados
Judit Olasz
Balazs Banky
Jozsef Toth
Maria Godeny
Francesco M. Marincola
Miklos Kasler
Yehuda Shoenfeld
Publication date: 01-02-2015
Publisher: Springer US
Published in: Immunologic Research / Issue 1-2/2015
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-014-8600-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2015

Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature

Interdisciplinary exchange of ideas: progestagens for autoimmunity, biologics for pregnancy complications

The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Diagnostics and environmental factors

Erratum to: Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I